secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0000950170-23-039057
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR Q2 2023 net loss $77.7M; FDA accepts exa-cel BLAs with PDUFA Dec 8 for SCD
--------------------------------------------------------------------------------

- FDA accepted BLAs for exa-cel: Priority Review for SCD (PDUFA Dec 8, 2023), Standard Review for TDT (Mar 30, 2024).
- Net loss narrowed to $77.7M from $185.8M YoY; collaboration revenue $70M from Vertex milestone.
- Cash and accounts receivable $1,843M; R&D spend $101.6M, down from $123.2M Q2 2022.
- Vertex licensing: $100M upfront received, $70M milestone receivable, up to $230M additional milestones.
- Pipeline: CTX110/130/112/131 trials ongoing; in vivo CTX310 (ANGPTL3) enters clinic in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000095017023039057/0000950170-23-039057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000095017023039057/crsp-20230807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-039057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer